Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
During translation, ribosomes can pause on the nucleic acid. Researchers showed that collisions from incoming proteins get ...
A polypeptide’s potential variations are virtually ... but which may also confer weaker IP rights. Small molecule drugs carry less IP risk when using AI tools in screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback